It can be familial and associated with other autoimmune diseases
Those on semaglutide 2.4 mg lost an average of 15.3% of their body weight over 68 weeks, compared to just 2.6% in the placebo group
This makes it a combinatorial tool of choice for protocols testing synergy with: GIPR agonists (deconstructed tirzepatide, or dedicated GIPR molecules) to explore additive incretin effects FGF21 modulators to study hepatic metabolic synergy SGLT2 inhibitors (empagliflozin, dapagliflozin) to model cardio-renal combinations observed clinically MC4R antagonists to dissect the role of the melanocortin circuit in the central anorexigenic effect Exogenous leptin (in ob/ob) to map leptin-GLP-1 crosstalk in appetite control Synergy studies must plan a 2x2 factorial design (vehicle, compound A alone, compound B alone, combination) to allow statistical interaction analysis
Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, Parkinson Study Group-PROGENI Investigators (2009) Mutations in GBA are associated with familial Parkinson disease susceptibility and age at onset
